Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21393292 | 0.83 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL19574036 | 0.81 | ALDH1A1 (0.43) | KDM4EALDH1A1L3MBTL1HPGDSEGLN2 | |
| SCHEMBL21536492 | 0.71 | HSD11B1 (0.35) | AURKAGRK6HSD11B1 | |
| SCHEMBL2737290 | 0.68 | ALDH1A1 (0.46) | KDM4EALDH1A1L3MBTL1HPGDSHSD11B1 | |
| SCHEMBL19574035 | 0.67 | APLNR (0.39) | KDM4EALDH1A1L3MBTL1HSD11B1 | |
| SCHEMBL21122380 | 0.67 | TRPV3 (0.32) | — | |
| SCHEMBL23006785 | 0.66 | IRAK4 (0.38) | KCNH2 | |
| SCHEMBL16311933 | 0.66 | ALDH1A1 (0.41) | AURKAGRK6KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL22481395 | 0.65 | ALDH1A1 (0.43) | KDM4EALDH1A1L3MBTL1HSD11B1KCNJ1 | |
| SCHEMBL15486717 | 0.65 | ALDH1A1 (0.43) | AURKAGRK6KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | AURKA 856/4885GRK6 161/4885KDM4E 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.